From $95.00 Repair Research BPC 5mg + TB 5mg A research peptide studied in controlled laboratory settings involving cellular signaling, peptide behavior, and tissue-related research pathway investigation
Its commonly used to dilute or dissolve peptides and other medications before injection
It is well tolerated
Product Information Chemical Data Analyte Name Glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine Molecular Formula C62 H98 N16 O22 SMILES CC(C)C[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)O InChI InChI=1S/C62H98N16O22/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-/m0/s1 IUPAC (4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-[(2S)-2-[(2S)-2-[[2-[[(1S)-5-amino-1-[(2S)-2-[[(1S)-2-[[(1S)-1-(carboxymethyl)-2-[[(1S)-1-(carboxymethyl)-2-[[(1S)-2-[[2-[[(1S)-1-[[(1S)-1-carboxy-2-methyl-propyl]carbamoyl]-3-methyl-butyl]amino]-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]pyrrolidine-1-carbonyl]pentyl]amino]-2-oxo-ethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-oxo-pentanoic acid Product Data Storage Temperature -20C Shipping Temperature Room Temperature Product Type Synthesis Tools
ChangLAdeyemoMKaragiannidisIVidelockEJBoweCShihWet al
The risk was driven by the synthetic progestin What Modern Research Shows The French E3N cohort study (80,000+ women) found no increased breast cancer risk with bioidentical estradiol plus micronized progesterone for up to 5 years The "timing hypothesis" shows women starting HRT within 10 years of menopause receive cardiovascular benefit rather than harm The Danish Osteoporosis Prevention Study showed reduced heart failure, MI, and mortality over 16 years of follow-up Major medical organizations NAMS, Endocrine Society, and IMS now endorse HRT for symptomatic women within the appropriate window Risks and Contraindications Hormone therapy is not risk-free, and we believe in complete transparency
